IRVINE, Calif., Sept. 07, 2017 -- Khang & Khang LLP (the “Firm”) announces the filing of a securities class action lawsuit against Dr. Reddy’s Laboratories Limited (“Dr. Reddy’s” or the “Company”) (NYSE:RDY). Investors who purchased or otherwise acquired shares between June 17, 2015 and August 10, 2017, inclusive (the “Class Period”), are encouraged to contact the Firm in advance of the October 24, 2017 lead plaintiff motion deadline.
If you purchased Dr. Reddy’s shares during the Class Period, please contact Joon M. Khang, Esq., of Khang & Khang LLP, 4000 Barranca Parkway, Suite 250, Irvine, CA 92604, by telephone at (949) 419-3834, or by e-mail at [email protected].
There has been no class certification in this case yet. Until certification occurs, you are not represented by an attorney. You may choose to take no action and remain a passive class member as well.
According to the Complaint, throughout the Class Period, Dr. Reddy’s made false and/or misleading statements, and/or failed to disclose, that the Company lacked an effective corporate quality system; and thus, its public statements were materially false and misleading at all relevant times. On August 10, 2017, Dr. Reddy’s disclosed that the Regulatory of Germany (Regierung von Oberbayern) did not renew the good manufacturing practices compliance certificate of a formulations manufacturing unit of its German subsidiary Betapharm Arzneimittel, located in Hyderabad, India, following a recent inspection of the plant. When this news was announced, shares of Dr. Reddy’s lowered in value materially, which caused investors harm according to the Complaint.
If you wish to learn more about this lawsuit, or if you have any questions concerning this notice or your rights, please contact Joon M. Khang, Esq., a prominent litigator for almost two decades, by telephone at (949) 419-3834, or via e-mail at [email protected].
This press release may constitute Attorney Advertising in some jurisdictions.
Contact Joon M. Khang, Esq. Telephone: 949-419-3834 Facsimile: 949-225-4474 [email protected]


SpaceX Prioritizes Moon Mission Before Mars as Starship Development Accelerates
TrumpRx Website Launches to Offer Discounted Prescription Drugs for Cash-Paying Americans
Nvidia, ByteDance, and the U.S.-China AI Chip Standoff Over H200 Exports
Hims & Hers Halts Compounded Semaglutide Pill After FDA Warning
Global PC Makers Eye Chinese Memory Chip Suppliers Amid Ongoing Supply Crunch
Indian Refiners Scale Back Russian Oil Imports as U.S.-India Trade Deal Advances
Rio Tinto Shares Hit Record High After Ending Glencore Merger Talks
Kroger Set to Name Former Walmart Executive Greg Foran as Next CEO
American Airlines CEO to Meet Pilots Union Amid Storm Response and Financial Concerns
Sony Q3 Profit Jumps on Gaming and Image Sensors, Full-Year Outlook Raised
Anta Sports Expands Global Footprint With Strategic Puma Stake
Samsung Electronics Shares Jump on HBM4 Mass Production Report
Innovent Biologics Shares Rally on New Eli Lilly Oncology and Immunology Deal
SoftBank Shares Slide After Arm Earnings Miss Fuels Tech Stock Sell-Off
Prudential Financial Reports Higher Q4 Profit on Strong Underwriting and Investment Gains
DBS Expects Slight Dip in 2026 Net Profit After Q4 Earnings Miss on Lower Interest Margins 



